Prabhat Das, MD
Pulmonary Disease · Lakewood, NJNPI 1417983461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Boston Scientific at 46.7% of the total. Reporting peaked in 2019 at $143 and has fallen 79.9% since, to $29 in 2023. That places this record below the midpoint for pulmonary disease clinicians in NJ, where the typical reported total is $2,135.
Across 11 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$121
- AstraZeneca$60
- Mylan Specialty L.p.$59
- Philips North America LLC$20
What the payments were for
- Food & beverage$24896%
- Education$124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $121 |
| AstraZeneca | 5 | $60 |
| Mylan Specialty L.p. | 4 | $59 |
| Philips North America LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$121
How this compares
$259 in reported general payments places this provider in the 15th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $43,149 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,812 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $14,752 |
| JardianceEmpagliflozin | 11 | $7,851 |
| XareltoRivaroxaban | 16 | $7,765 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $2,928 |
| Sucralfate | 31 | $1,987 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,957 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,777 |
| Pantoprazole Sodium | 157 | $1,473 |
| Midodrine Hcl | 18 | $1,411 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 47 | $1,132 |
| Ranolazine ErRanolazine | 12 | $1,110 |
| Metoprolol Succinate | 96 | $1,081 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,062 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lakewood
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.